Long-Term Efficacy and Safety Analysis of First-Line Tislelizumab in Patients With Advanced Squamous NSCLC: a Retrospective Real-World Study Based on RATIONALE-307
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 109
- 试验地点
- 1
- 主要终点
- Overall Survival (OS)
研究概览
简要总结
The study aims to retrospectively collect long-term survival data from patients who received first-line tislelizumab combined with chemotherapy in the RATIONALE-307 trial, in order to enrich the evidence on long-term benefits in advanced squamous NSCLC patients from immunotherapy and to identify patients deriving greater clinical advantage.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with squamous NSCLC who participated in the RATIONALE-307 trial and had no documented death before study completion
排除标准
- •Patients who had a documented death before study completion in the RATIONALE-307 trial
研究组 & 干预措施
Extension Cohort
Patients with squamous NSCLC who participated in the RATIONALE-307 trial and had no documented death before study completion
干预措施: No intervention (Other)
结局指标
主要结局
Overall Survival (OS)
时间窗: Defined as the time from the date of randomization in the RATIONALE-307 trial to the date of death from any cause occurring on or before December 31, 2025.
次要结局
未报告次要终点
研究者
Zhijie Wang
Chief Physician
Cancer Institute and Hospital, Chinese Academy of Medical Sciences